Search results
Results from the WOW.Com Content Network
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.The company has three commercially approved medicines: Spinraza (), Tegsedi (), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA ...
(Reuters) -The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's ...
Ionis Pharmaceuticals Stock Price And Volume Action Ionis Pharmaceuticals (NASDAQ:IONS) is currently down 17.47% to a price of $46.29. Tuesday the stock has been traded at a volume of 2.55 million ...
Clinical trial number NCT04136184 for "NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy" at ClinicalTrials.gov
At that time, only Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (formerly Isis Pharmaceuticals until December 2015) [2] was conducting significant research with this technology. Antisense is a short span of oligonucleotides – modified DNA structures ranging from about 12-24 bases that selectively bind to specific RNA.
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 158.06% and 11.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease. The drug ...
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.